The Alzheimer’s drug pipeline is healthier than you might think
It reflects a more nuanced understanding of the disease
OF ALL THE medical challenges that scientists have faced, Alzheimer’s disease, the most common form of dementia, has been one of the trickiest. Between 1995 and 2021 private money spent on Alzheimer’s research totalled $42.5bn, but more than 140 trials failed to deliver a single drug capable of slowing the disease. Yet the tide may be turning. There are two working drugs, offering modest benefits, on the market. A new review paper suggests more could soon follow.
Explore more
How much coffee is too much?
Studies suggest moderate consumption is harmless. It may even be beneficial
Elon Musk’s plans to go to Mars next year are toast
SpaceX’s Starship fails for a third time in a row
The decoding of ancient Roman scrolls is speeding up
More data, and a more powerful particle accelerator, should pay dividends
Old oil paintings are suffering from chemical “acne”
Conservators are scrambling to rescue them
Snakes may have once faced a vicious enemy: the humble ant
Scientists believe that could be why the slithering reptiles developed toxic tails
Aron D’Souza, the brash brain behind the “doping Olympics”
The president of the Enhanced Games wants to push forward human evolution